M. Koufany

发表

Effect of peroxisome proliferator activated receptor (PPAR)gamma agonists on prostaglandins cascade in joint cells.

P. Poleni, S. Sébillaud, P. Netter, 2006, Biorheology.

Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)γ agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1β-stimulated rat chondrocytes: evidence for PPARγ-independent inhibition by 15-deoxy-Δ12,14prostaglandin J2

M. Galteau, S. Sébillaud, P. Netter, 2005, Arthritis research & therapy.

Oxidative stress-induced expression of HSP70 contributes to the inhibitory effect of 15d-PGJ2 on inducible prostaglandin pathway in chondrocytes.

P. Reboul, S. Hupont, P. Netter, 2014, Free radical biology & medicine.

Evidence for species differences in the regulation of MMPs by all-trans retinoic acid in cytokine-stimulated chondrocytes.

S. Sébillaud, P. Netter, J. Jouzeau, 2008, Biorheology.

Lack of Adipocytes Alters Hematopoiesis in Lipodystrophic Mice

B. Desvergne, N. Bonnet, Carine Winkler, 2018, Front. Immunol..

Agonists of peroxisome proliferators-activated receptors (PPAR) α, β/δ or γ reduce transforming growth factor (TGF)-β-induced proteoglycans' production in chondrocytes

P. Poleni, S. Sébillaud, P. Netter, 2007 .

Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.

S. Boyault, M. Francois, S. Sébillaud, 2005, Arthritis and rheumatism.

The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.

D. Chappard, G. Weryha, P. Netter, 2013, Arthritis and rheumatism.

Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.

J. Jouzeau, D. Moulin, M. Koufany, 2014, Bio-medical materials and engineering.

Association between rheumatoid arthritis and systemic mastocytosis: a case report and literature review

D. Loeuille, I. Latar, P. Netter, 2016, Clinical Rheumatology.

All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation

S. Sébillaud, P. Netter, J. Jouzeau, 2008, Arthritis research & therapy.

Response to: ‘Spontaneous hypertensive rat exhibits bone and meniscus phenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA?’ by Chan and Wen

A. Pizard, C. Guillaume, A. Bianchi, 2017, Annals of the rheumatic diseases.

Uncoupling of oxidative phosphorylation and Smac/DIABLO release are not sufficient to account for induction of apoptosis by sulindac sulfide in human colorectal cancer cells.

J. Merlin, P. Netter, J. Jouzeau, 2005, International journal of oncology.

Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis

S. Sébillaud, G. Weryha, P. Netter, 2008, Arthritis research & therapy.

[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].

S. Sébillaud, P. Netter, J. Jouzeau, 2008, Journal de la Societe de biologie.

Rosiglitazone induces interleukin‐1 receptor antagonist in interleukin‐1β–stimulated rat synovial fibroblasts via a peroxisome proliferator–activated receptor β/δ–dependent mechanism

S. Boyault, M. Francois, S. Sébillaud, 2005 .

FRI0017 Pharmacological Blockade of CCR3 Reduces Collagen-Induced Arthritis Severity

P. Reboul, D. Moulin, M. Koufany, 2016 .

Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans' production in chondrocytes.

P. Poleni, S. Sébillaud, P. Netter, 2007, Osteoarthritis and cartilage.

MicroRNA-29b Contributes to Collagens Imbalance in Human Osteoarthritic and Dedifferentiated Articular Chondrocytes

I. Behm-Ansmant, C. Branlant, J. Jouzeau, 2017, BioMed research international.

[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].

S. Sébillaud, P. Netter, J. Jouzeau, 2008, Journal de la Societe de biologie.

Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis

A. Pizard, C. Guillaume, A. Bianchi, 2017, Annals of the rheumatic diseases.

Contrasting effects of peroxisome-proliferator-activated receptor (PPAR) (cid:13) agonists on membrane-associated prostaglandin E 2 synthase-1 in IL-1 (cid:12) -stimulated rat chondrocytes: evidence for PPAR (cid:13) -independent inhibition by 15-deoxy- ∆ 12,14 prostaglandin J 2

M. Galteau, S. Sébillaud, J. Jouzeau, 2020 .